

Special Issue

Current Concept and Emerging Treatments of Bullous Skin Diseases

Message from the Guest Editor

Over the past two decades, biologic drugs have significantly improved the prognosis of autoimmune bullous skin diseases (ABSDs). However, there remains a constant need to search for new therapies. Proteins that determine the proper connection between epidermal cells or between the epidermis and dermis are targets for pathogenic autoantibodies in ABSDs. These proteins are encoded in genes whose mutations cause congenital bullous skin diseases (CBSDs). Therefore, specialists dealing with the pathogenesis of ABSDs gain knowledge by following the progress of research on CBSDs and vice versa. Modern treatment strategies for CBSDs include correction of mutations, protein replacement or the use of various cell therapies that alleviate the course of this group of diseases, but these approaches are not yet effective enough. Recent studies provide evidence for the involvement of the immune system and the production of pro-inflammatory cytokines in the pathogenesis of CBSDs. Therefore, some treatment strategies of ABSDs may prove useful in relieving symptoms of CBSDs. This Special Issue encourages submissions include reviews, original research, or clinical trials related to ABSDs or CBSDs.

Guest Editor

Prof. Dr. Cezary Kowalewski

Department of Dermatology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland

Deadline for manuscript submissions

25 August 2025



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/227693

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

[jcm](https://jcm.mdpi.com)





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).